Ampio Pharmaceuticals to present at the Oppenheimer Annual Healthcare Conference on December 11th, 2014

ENGLEWOOD, Colo., Dec. 4, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the 25^th Annual Oppenheimer Healthcare Conference on Thursday, December 11^th, 2014.  The presentation is scheduled for 11:30 AM Eastern Time at the Crown Plaza Hotel in New York City.

Josh Disbrow, Ampio's Chief Operating Officer and Chief Executive Officer of Ampio subsidiary Luoxis Diagnostics, and Holli Cherevka, Ampio's Senior Director of Clinical Development and Operations, will provide an update on the company's corporate and clinical development activities. 

Following the conference the corporate presentation may be accessed through the Ampio website, www.ampiopharma.com, on the "Presentations and Media" page.

About Ampio Pharmaceuticals:
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements:
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to the completion, timing and size of the registered direct offering, as well as risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
April Ramirez
Operations Coordinator
Ampio Pharmaceuticals, Inc.
373 Inverness Parkway, Englewood, CO 80112
Direct: (720) 437-6524

Logo - http://photos.prnewswire.com/prnh/20120516/MM09116LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-present-at-the-oppenheimer-annual-healthcare-conference-on-december-11th-2014-300004609.html

SOURCE Ampio Pharmaceuticals, Inc.